Corticosteroids Mediate Heart Failure-Induced Depression through Reduced σ1-Receptor Expression

Yasuharu Shinoda, Hideaki Tagashira, Md. Shenuarin Bhuiyan, Hideyuki Hasegawa, Hiroshi Kanai, Chen Zhang, Feng Han, Kohji Fukunaga

1 Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aramaki-Aoba, Aoba-ku, Sendai, Japan, 2 Division of Molecular Cardiovascular Biology, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 45229, United States of America, 3 Department of Electrical Engineering, Graduate School of Biomedical Engineering, Tohoku University, 6-6 Aramaki-Aoba, Aoba-ku, Sendai, Japan, 4 Department of Pharmacy, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, 31005, P. R. China

☯ These authors contributed equally to this work.
* kfukunaga@m.tohoku.ac.jp

Abstract

Cardiovascular diseases are risk factors for depression in humans. We recently proposed that σ1 receptor (σ1R) stimulation rescued cardiac hypertrophy and heart failure induced by transverse aortic constriction (TAC) in mice. Importantly, σ1R stimulation reportedly ameliorates depression-like behaviors in rodents. Thus, we hypothesized that impaired σ1R activity in brain triggers depression-like behaviors in animals with cardiovascular disease. Indeed, here we found that cardiac hypertrophy and heart failure induced by TAC were associated with depression-like behaviors concomitant with downregulation of σ1R expression in brain 6 weeks after surgery. σ1R levels significantly decreased in astrocytes in both the hippocampal CA1 region and dentate gyrus. Oral administration of the specific σ1R agonist SA4503 (0.3–1.0mg/kg) significantly improved TAC-induced depression-like behaviors concomitant with rescued astrocytic σ1R expression in CA1 and the dentate gyrus. Plasma corticosterone levels significantly increased 6 weeks after TAC, and chronic treatment of mice with corticosterone for 3 weeks elicited depression-like behaviors concomitant with reduced astrocytic σ1R expression in hippocampus. Furthermore, the glucocorticoid receptor antagonist mifepristone antagonized depressive-like behaviors and ameliorated decreased hippocampal σ1R expression in TAC mice. We conclude that elevated corticosterone levels trigger hippocampal σ1R downregulation and that σ1R stimulation with SA4503 is an attractive therapy to improve not only cardiac dysfunction but depression-like behaviors associated with heart failure.
Introduction

The prevalence of depression in heart failure (HF) patients has drawn attention because it is associated with poorer clinical outcomes [1, 2]. Indeed, depression following myocardial infarction (MI) is associated with higher morbidity and mortality [3]. Current American College of Cardiology/American Heart Association guidelines for coronary artery bypass graft (CABG) surgery, acute MI, and chronic angina all recommend evaluation of depression and subsequent therapy [4]. Notably, administration of selective serotonin reuptake inhibitors (SSRIs) to MI patients reduces post-MI morbidity and mortality [3]. However, it remains unclear whether MI causes depression, because the relationship of the heart to emotional responses is largely unknown.

Since selective serotonin reuptake inhibitors (SSRIs) such as fluvoxamine and sertraline are potent σ₁R ligands, we recently focused on cardioprotective mechanisms of SSRI through the σ₁R in heart failure models using transverse aortic constriction (TAC) mice and ovariectomised rats [5–7]. We found that fluvoxamine, which exhibits a high σ₁R affinity (Ki = 36 nM), but not paroxetine, which binds with lower affinity (Ki = 1893 nM), markedly rescued heart failure and cardiac dysfunction in both TAC models of mice and rats [5, 7]. In addition, we previously confirmed that the selective σ₁R agonist SA4503 (Ki = 4.4 nM) antagonizes cardiac dysfunction associated with heart failure in mice [8]. Interestingly, σ₁R is highly expressed in neonatal rat cardiomyocytes and in brain [8, 9]. σ₁R protein levels in left ventricle markedly decreased accompanied by progression of left ventricular hypertrophy in TAC mice and σ₁R protein expression was significantly and positively correlated with impaired LV fractional shortening [7].

σ₁R protein is predominantly localized to the mitochondria-associated ER membrane (MAM) where it functions as molecular chaperone of the IP₃ receptor (IP₃R), thereby regulating Ca²⁺ transport into mitochondria from the ER [10]. In cultured cardiomyocytes, σ₁R stimulation inhibits angiotensin II-induced hypertrophy and cardiomyocyte injury by promoting mitochondrial Ca²⁺ transport and ATP production [8]. σ₁R knockdown by siRNA totally eliminates σ₁R-mediated cardioprotection in cultured cardiomyocytes, suggesting that SSRI or SA4503 directly acts on σ₁R expressed in cardiomyocytes.

Recently, Ito et al. reported that pressure overload- and high salt diet-induced heart failure elicits depression-like behaviors in mouse with concomitant reduction of σ₁R levels in brain, and that sympathetic nervous system suppression by administration of a σ₁R agonist in the CNS antagonized both σ₁R downregulation and impaired LV fractional shortening [11]. However, how mechanistically σ₁R is downregulated and in what cells remains unclear.

Here, we report that TAC surgery induces depression-like behaviors evident 6 weeks later and that σ₁R stimulation with the high affinity σ₁R agonist SA4503 ameliorates those behaviors. We also show that σ₁R is preferentially downregulated following TAC in hippocampal astrocytes. Depressive-like behaviors and decreased σ₁R levels in TAC mice were ameliorated by treatment with the glucocorticoid receptor inhibitor mifepristone. Finally, we demonstrated that SA4503 treatment ameliorates TAC-induced depression-like behaviors by rescuing σ₁R protein expression in brain and heart. We conclude that σ₁R agonists such as fluvoxamine and SA4503 are potential therapeutics to treat depression following cardiovascular disease.

Material and Methods

Materials

Reagents and antibodies were obtained from the following sources: anti-σ₁R antibody (Abcam, Cambridge, UK); anti-glial fibrillar acidic protein (GFAP) (Sigma, St. Louis, MO); anti-β-
tubulin antibody (Sigma, St. Louis, MO). SA4503 was synthesized in Laboratory of Medicinal Chemistry, Zhejiang University according to the method of Fujimura et al. [12]. NE-100 (N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy) phenyl]-ethylamine monohydrochloride) was generously supplied by Taisho Pharmaceutical Co. Ltd (Ohmiya, Japan). Paroxetine and mifepristone was purchased from Sigma and Cayman Chemical (Ann Arbor, MI), respectively. Other reagents were of the highest quality available (Wako Pure Chemicals, Osaka, Japan).

Animals and Operations

All procedures for handling animals complied with the Guide for Care and Use of Laboratory Animals and were approved by the Animal Experimentation Committee of Tohoku University Graduate School of Pharmaceutical Sciences. Adult male ICR mice weighing 35 to 40 g were obtained from Nippon SLC (Hamamatsu, Japan). Ten-week-old males were acclimated to the local environment for 1 week, which included housing in polypropylene cages at 23 ± 1°C in a humidity-controlled environment maintained on a 12-h light/dark schedule (lights on 8:00 AM–8:00 PM). Mice were provided food and water ad libitum. Transverse aortic constriction (TAC) was performed as described [7] on male ICR mice under anesthesia using a mixture of ketamine (100 mg/kg, i.p.) (Daiichi Sankyo Pharmaceutical Co. Ltd, Tokyo, Japan) and xylazine (5 mg/kg, i.p.) (Sigma, St. Louis, MO). Adequate depth of anesthesia was confirmed by a negative toe-pinch reflex. If anesthesia was not sufficient, then a top-up dose of 20% of the initial dose was given.

Experimental Design

ICR mice were randomly separated into six experimental groups: 1) sham (n = 7), 2) TAC for 6 weeks (n = 8), 3) TAC plus SA4503 (0.1 mg/kg, p.o.) treatment (SA 0.1) (n = 7), 4) TAC plus SA4503 (0.3 mg/kg, p.o.) treatment (SA 0.3) (n = 6), 5) TAC plus SA4503 (1.0 mg/kg, p.o.) treatment (SA 1.0) (n = 8), 6) TAC plus SA4503 (1.0 mg/kg, p.o.) plus NE-100 treatment (1.0 mg/kg, p.o.) (SA 1.0+NE) (n = 8), 7) TAC plus paroxetine (0.4 mg/kg, p.o.) (n = 7). SA4503 and NE-100 were dissolved in a 0.9% saline solution. Paroxetine was dissolved in 0.5% carboxymethylcellulose. Vehicle, SA4503 and NE-100 (1.0 mg/kg) were administered orally (once daily) over the last 4 weeks of TAC using a metal gastric zonde for mice in a volume of 1ml/100g body weight, starting from the onset of aortic banding. To define the effect of corticosterone (CORT) on σ1R expression, ICR mice were randomly separated into three experimental groups: 1) vehicle (n = 8), 2) CORT for 1 week (n = 11), and 3) CORT for 3 weeks (n = 8). CORT (20 mg/kg, s.c.) was was dissolved in 0.5% carboxymethyl cellulose solution and injected for 1 or 3 weeks (once daily) in a volume of 1ml/100g of body weight as described [13]. To investigate mifepristone effects, ICR mice were separated into four groups: 1) sham plus vehicle (n = 6), 2) sham plus mifepristone (50 mg/kg s.c.) (n = 7), 3) TAC plus vehicle (n = 4), and 4) TAC plus mifepristone (50 mg/kg, s.c.) (n = 4). Mifepristone was dissolved in PEG400 vehicle (Nacalai Tesque, Inc., Kyoto, Japan). Vehicle and mifepristone were injected subcutaneously daily for 4 weeks starting 2 weeks after TAC surgery.

Tail Suspension Test

The tail suspension test is widely used in mice to test anti-depressant activity. The test is based on the fact that animals subjected to the short-term, inescapable stress of being suspended by the tail will develop an immobile posture. The depressed mice show increased immobility time. Immobility duration following tail suspension was scored according to the method of Steru et al. [14]. In brief, acoustically and visually isolated mice were suspended 50 cm above the floor by adhesive tape placed approximately 1 cm from the tip of the tail. Immobility time was
recorded during a 5-min period. Mice were considered immobile only when they hung passively and remained completely motionless.

**Forced Swim Test**

The forced swim test is also widely used to assess antidepressant-like activity. Mice were placed individually in glass cylinders (height: 25 cm, diameter: 16 cm) filled 20 cm of water at 24°C, and the duration of immobility time in a 5-min test was scored as described by Porsolt et al. [15]. Mice were judged "immobile" when they ceased struggling and remained floating motionless in the water, making only movements necessary to keep their head above water.

**Sucrose Preference Test**

Mice were randomly placed into cages with two bottles containing drinking water and 1% sucrose solution. Bottle's weights were measured once in each day and location was switched in the next day to prevent bias from preference for location. Tests were conducted for five consecutive days, and sucrose preference (%) was calculated as ratio of 1% sucrose consumption to total consumption.

**Echocardiography and Measurement of Cardiac Hypertrophy**

Noninvasive echocardiographic measurements were performed as described [7, 8]. Briefly, procedures were performed in mice anesthetized with pentobarbital-NaCl/EtOH solution (0.05 g/kg, i.p.) using ultrasonic diagnostic equipment (SSD-6500; Aloka, Tokyo, Japan) equipped with a 10-MHz linear array transducer (UST-5545; Aloka). The heart was imaged in a two-dimensional parasternal short-axis view, and an M-mode echocardiogram of the midventricle was recorded at the level of the papillary muscles. Diastolic and systolic LV wall thickness, LV end-diastolic diameter (LVEDD) and LV end-systolic diameter (LVESD) were measured, all from leading edge to leading edge according to American Society of Echocardiography guidelines. The percentage of LV fraction shortening (LV%FS) was calculated as \([\frac{\text{LVEDD}—\text{LVESD}}{\text{LVEDD}}\times 100]\). After animals were sacrificed by cervical spine fracture dislocation, the thoracic cavity was opened, and hearts were immediately harvested and weighed. Blood pressure was measured using the tail-cuff method (BP-98A-L, Softron, Tokyo, Japan), according to the manufacturer’s protocol.

**Western Blot Analysis and Measurement of ATP Content**

Frozen samples were homogenized as described [8]. Western blot analysis was performed as previously described [7, 16]. Blots were subjected to the ECL immunoblotting detection system (Amersham Biosciences, U.K.), and emitted light was captured by a Luminescent Image Analyzer (LAS-4000 mini, Fuji Film, Tokyo, Japan) attached to a CCD camera. Densitometric quantification of blot signals was performed with Image Gauge Ver3.0 (Science Lab, Fuji Film, Tokyo, Japan). ATP measurement was performed using an ATP assay kit (Toyo Ink, Tokyo, Japan), according to the manufacturer’s protocol as described [17, 18]. Briefly, frozen samples were homogenized in homogenate buffer (0.25M sucrose, 10mM HEPES-NaOH, pH 7.4), and lysates were cleared by centrifugation at 1000g for 10 min at 4°C. Supernatants were collected, and supernatant proteins were solubilized in extraction buffer. After a 30 min incubation, luciferin buffer was added to each sample and oxyluciferin was detected using a luminometer (Gene Light 55, Microtec, Funabashi, Japan).
Measurement of Corticosterone Levels in Plasma and Brain Tissue

Corticosterone measurement was performed using a corticosterone EIA kit (Enzo Life Sciences, Farmingdale, NY), according to the manufacturer’s protocol. Plasma samples were collected as previously reported [19]. Briefly, the mice were decapitated and then blood was collected into tubes that contained EDTA. After centrifugation at 4°C, 1500×g for 10 min, plasma was aliquoted and stored at -80°C until CORT analysis.

Immunohistochemistry

Immunohistochemistry was carried out as described [20, 21]. Briefly, 50 μm sliced mouse brain tissues were incubated 3 days at 4°C with anti-σ1R antibody (1:200) and anti-GFAP antibody (1:250) in 0.5% Blocking Reagent (TSA Fluorescence system, PerkinElmer, Inc. Waltham, MA). After washing, sections were incubated for 24hr with a species-specific secondary antibody conjugated with Alexa 594 and Alexa 488 in 0.5% blocking reagent. For nuclear staining, sections were incubated with DAPI (Vector Laboratories, Burlingame, CA). Sections of rat heart tissue embedded in VECTASHIELD (Vector Laboratories, Burlingame, CA) were examined using a fluorescence microscope. Immunofluorescent images were obtained with confocal laser scanning microscope (LSM700, Carl Zeiss Microscopy).

Statistical Analysis

Values are represented as means ± standard error of the mean (S.E.M.). Comparison between two experimental groups was made using the unpaired Student’s t test. Other results were evaluated for differences using two- or one-way analysis of variance (ANOVA), followed by multiple comparisons using Dunnett’s test. P<0.05 was considered statistically significant.

Results

Time Course Analysis of Depression-Like Behaviors and σ1R Expression

To define σ1R function in TAC-induced depression-like behaviors, we first evaluated temporal changes in both depression-like behaviors and brain σ1R expression in mice after TAC or sham surgery. In TAC animals, behaviors indicative of depression were observed following analysis of forced swimming and tail suspension tasks 6 weeks after TAC (P<0.01 vs. sham in forced swimming task and P<0.05 vs. sham in tail suspension task) (Fig 1A and 1B). Importantly, σ1R expression in the hippocampal CA1 region and dentate gyrus (DG) but not in medial prefrontal cortex (mPFC) region markedly decreased both at both 4- and 6-week times points after TAC (P<0.05 vs. sham in CA1 at 4 and 6 weeks after TACs, and P<0.01 vs. sham in DG at both 4 and 6 weeks) (Fig 1C and 1D). Temporal changes in σ1R levels were comparable to those previously reported in the heart [7].

Since σ1R stimulation with the novel σ1R agonist SA4503 reportedly improves depression-like behaviors in olfactory bulbectomized rats [22], we next tested potential anti-depression effects of SA4503 in TAC mice. As expected, SA4503 treatments starting 2 weeks after TAC and continuing for 4 weeks dose-dependently antagonized increased immobility times, which are indicative of depression, seen in the forced swimming task (P<0.01 vs. TAC-vehicle for SA 0.3 and SA 1.0) (Fig 1E). In tail suspension task, SA4503 treatment (1.0 mg/kg) reduced immobility times to identical levels to sham mice (Fig 1F). However, mice treated with both SA4503 and NE100 showed similar increase in immobility times with sham mice (P<0.01 vs. sham for SA 1.0+NE in forced swimming task, P<0.05 vs. sham for SA 1.0+NE in tail suspension task) (Fig 1E and 1F). Treatment with paroxetine (0.4 mg/kg), a conventional SSRI which has a
relatively low affinity of $\sigma_1 R$ [23], partially but significantly reduced immobility times of TAC mice in forced swimming task (63.4 ± 5.9 sec) ($P<0.05$ vs. TAC-vehicle), but not in tail suspension task (102.3 ± 10.8 sec)(S1 Fig). In sucrose preference test, sucrose preference was significantly decreased in TAC mice ($P<0.01$ vs. sham) (Fig 1G). SA4503 treatment recovered sucrose preference in TAC mice ($P<0.05$ vs. TAC veh) and the effect was blocked by co-administration of NE100 (Fig 1G). Overall, these findings indicate that SA4503 treatment ameliorates TAC-induced depression-like behaviors in TAC mice. 

Effect of SA4503 Treatment on Hippocampal $\sigma_1 R$ Expression

Since $\sigma_1 R$ stimulation by SA4503 ameliorated TAC-induced depression-like behaviors, we next asked whether treatment of mice with SA4503 restored brain $\sigma_1 R$ expression using the same experimental design employed for behavioral tests. SA4503 administration at 1 mg/kg significantly restored $\sigma_1 R$ levels in both CA1 ($P<0.05$ vs. TAC-vehicle for SA 1.0) and DG regions ($P<0.01$ vs. TAC-vehicle for SA 1.0) (Fig 2A and 2B). Co-administration of NE-100 failed to
abolish SA4503-induced increases in σ1R expression (Fig 2A and 2B). We also analyzed expression levels of another ER chaperone protein, 78 kDa glucose-regulated protein (GRP78, Bip), which makes a complex with σ1R [10]. Bip expression levels in CA1 and DG regions were not significantly changed among four groups (sham, TAC-vehicle, SA1.0 and SA1.0+NE) (CA1: $F(3,8) = 1.707$, $P = 0.242$, DG: $F(3, 8) = 0.033$, $P = 0.991$) (S2 Fig).

As previously reported by Tagashira et al. [8], SA4503 administration at 0.3 and 1 mg/kg significantly rescued σ1R downregulation seen in heart following TAC ($P<0.01$ vs. TAC-vehicle for SA 0.3 and SA 1.0) (Fig 2C and 2D). In that study we also found that SA4503 treatment immediately after surgery increased heart ATP production concomitant with improved heart function [8]. In the present study, we found that SA4503-mediated restoration of ATP production also occurred in hippocampus ($P<0.05$ vs. TAC-vehicle for SA 1.0) (Fig 2E), and co-administration of NE-100 abolished this effect ($P<0.01$ vs. SA 1.0) (Fig 2E). We also confirmed that SA4503 treatment restored ATP production in the heart ($P<0.05$ and $P<0.01$ vs. TAC-vehicle for SA 0.3 and 1.0 mg/kg, respectively) (Fig 2F). Taken together, SA4503-induced restoration of σ1R and ATP levels positively correlates with its anti-depressive action.
Immunohistochemical Changes in Hippocampal σ1R Expression

We next defined hippocampal regions in which σ₁R is downregulated using immunohistochemistry. In CA1, σ₁R was predominately expressed in astrocytes (GFAP-positive cells) in the molecular layer and faintly in pyramidal neurons (see DAPI-positive cells; Fig 3A). Accordingly, σ₁R immunoreactivity in both astrocytes and neurons in CA1 significantly decreased by 6 weeks after TAC (Fig 3A). On the other hand, when we assessed the number of living neurons by DAPI staining, TAC had no effect on the total number of neurons in CA1 region at 6 weeks after TAC (71.17±6.44 cells (sham) vs. 70.00±3.11 cells (TAC 6 weeks), respectively (0.35 μm×0.35 μm region)). We also confirmed that the number of GFAP-positive cells in CA1 was comparable in both TAC and sham-operated mice (16.5±1.71 cells (sham) vs. 12.25±0.85 cells (TAC 6 weeks), respectively (in a 0.35 μm×0.35 μm region)). Likewise, in the DG, σ₁R was predominantly expressed in astrocytes in both molecular layer and hilus regions of the hippocampus. σ₁R levels markedly decreased by 6 weeks after TAC (Fig 3B). Finally, the total number of GFAP-positive cells in DG did not change in TAC mice (23.5±2.02 cells (sham) vs. 21.0±2.27 cells (TAC 6 weeks), respectively (in a 0.35 μm×0.35 μm region)).

Since σ₁R expression decreased primarily in hippocampal astrocytes (Fig 3A and 3B), we confirmed the effect of SA4503 treatment on σ₁R expression using immunohistochemistry. SA4503 treatment of mice subjected to TAC rescued σ₁R expression primarily in CA1 astrocytes, not in pyramidal neurons (Fig 3A). Co-administration with NE-100 did not eliminate SA4503-mediated increases in astrocytic σ₁R expression (Fig 3A). In DG, SA4503 treatment also restored σ₁R expression primarily in astrocytes (Fig 3B), and NE-100 co-administration did not eliminate these effects (Fig 3B). Taken together, SA4503-induced restoration of hippocampal σ₁R levels preferentially occurs in astrocytes.

Effect of SA4503 Treatment on Corticosterone Levels in Plasma and Hippocampal Tissue

We next addressed potential causes of hippocampal σ₁R downregulation following TAC. Increases in plasma corticosterone (CORT) levels reportedly occur in depressed patients and are a factor in stress-induced depression [24–26]. Thus, we investigated CORT levels following TAC in plasma and hippocampal tissue by ELISA. As expected, plasma CORT levels increased in TAC mice at 4- and 6-week time points after TAC surgery (P<0.01 vs. sham for 4 and 6 weeks TAC, respectively) (Fig 4A). In hippocampal tissues, however, CORT levels were not significantly changed but tended to increase in TAC mice (1.11 ± 0.11 ng/mg tissue (sham) vs. 1.35 ± 0.16 ng/mg tissue (TAC 6 weeks) (P = 0.51) respectively.) We next investigated σ₁R expression in a CORT-induced depressive mouse model (Fig 4B–4G). CORT administration over a 3-week period increased immobility time in forced swimming (P<0.05 vs. vehicle) (Fig 4B). CORT treatment slightly increased immobility time in tail suspension task, however, there was no statically significance (Fig 4C). Most importantly, CORT administration decreased σ₁R expression at 1- and 3-week time points in hippocampus, including CA1 and DG (P<0.05 vs. control for 1 week CORT in CA1 region, and P<0.01 vs. control for 3 week CORT in CA1 region and for both 1 and 3 weeks CORT in DG region) (Fig 4D and 4E).

We also asked whether hippocampal σ₁Rs are downregulated after CORT administration using immunohistochemistry. In CA1, endogenous σ₁R expression markedly decreased at 1 and 3 week time points after CORT treatment in both astrocytes and neurons (Fig 4P). Likewise, in the DG, expression of endogenous σ₁Rs in astrocytes also markedly decreased at 1 and 3 week time points following CORT treatment (Fig 4G). These findings suggest that elevated plasma CORT levels underlie TAC-induced σ₁R downregulation, especially in hippocampal astrocytes. Furthermore, we analyzed σ₁R expression levels in heart left ventricles. CORT
Fig 3. Effect of SA4503 treatment on \( \sigma_1 \)R expression in hippocampal astrocytes. A: Immunofluorescence showing localization of \( \sigma_1 \)R (red) with the astrocyte marker GFAP (green) and DAPI (blue) in the CA1 region 6 weeks after TAC surgery with or without drug treatment for the last 4 weeks. B: Immunofluorescence showing localization of \( \sigma_1 \)R (red) with GFAP (green) and DAPI (blue) in DG 6 weeks after TAC surgery with or without drug treatment for last 4 weeks. TAC mice were treated with SA4503 (0.1, 0.5 or 1.0 mg/kg) or SA4503 (1.0 mg/kg) plus NE-100 (1.0 mg/kg), as indicated. Boxed regions in all panels are magnified in adjacent right-hand panels.

doi:10.1371/journal.pone.0163992.g003
treatment for both 1 and 3 weeks failed to alter σ₁R expression in heart (veh: 100 ± 6.6%, CORT 1 week: 88.1 ± 7.1%, and CORT 3 week: 107.9 ± 9.3%) (n = 5–6). These results indicate that increased plasma CORT in TAC mice triggers σ₁R reduction in the hippocampus but not in the heart.

Effect of Mifepristone on Depression-Like Behaviors and σ₁R Expression in TAC Mice

Next, we asked whether pharmacological inhibition of glucocorticoid receptors would eliminate TAC-induced depressive-like behaviors and/or decrease hippocampal σ₁R expression. Treatment on TAC mice with mifepristone slightly antagonized increased immobility times seen in forced swimming (P = 0.38) (Fig 5A), however completely abolished TAC-induced increase in immobility time in tail suspension task (P<0.05 vs. TAC-vehicle for TAC-mifepristone) (Fig 5B). Moreover, mifepristone treatment of TAC mice significantly rescued reduced σ₁R expression seen in hippocampal CA1 and DG (P<0.01 and P<0.05 vs. TAC-vehicle for TAC-mifepristone in CA1 and DG, respectively), but had no effect on σ₁R expression in sham
mice (Fig 5C and 5D). These results suggest that elevated CORT levels partially function in depression-like behaviors and decreased hippocampal σ₁R expression in TAC mice.

SA4503 Treatment Ameliorates Myocardial Dysfunction in TAC Mice

We previously documented that SA4503 administration immediately after TAC surgery rescues cardiac dysfunction [8]. Here, we confirmed those findings when SA4503 was administered starting at 2 weeks after surgery. Like our previous findings [8], TAC mice showed decreases in LV fractional shortening (FS) and increases in left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD) (P<0.01 vs. sham) compared with sham-operated mice (Fig 6A–6D). SA4503 treatment dose-dependently rescued decreased FS (P<0.05 vs. TAC-vehicle for SA 0.3 and SA 1.0) (Fig 6B) and increased LVESD (P<0.05 vs. TAC-vehicle for SA 0.1, SA 0.3 and SA 1.0) (Fig 6C). Co-administration of NE-100 abolished SA4503-mediated amelioration of cardiac dysfunction, as indicated by decreased FS and increased LVESD (P<0.01 vs. TAC-vehicle for SA 1.0) (Fig 6B and 6C). Also, TAC mice treated with vehicle, both SA4503 and NE100 showed significant increase in LVEDD (P<0.01 and P<0.05 vs. sham for TAC-vehicle and SA 1.0+NE) (Fig 6D). SA4503 treatment significantly and dose-dependently rescued the HW-to-BW ratio (P<0.01 vs. TAC-vehicle for SA 1.0) (Fig 6E). Co-administration of NE-100 abolished SA4503 inhibition of TAC-induced hypertrophy, as indicated by HW-to-BW (P<0.01 vs. TAC-vehicle for SA 1.0) (Fig 6E). We conclude that the anti-pathological hypertrophic effect of SA4503 on TAC mice is mediated by σ₁R stimulation in vivo.
Ito et al. previously reported that suppression of sympathetic nerve activity by a different $\sigma_1$ agonist, PRE084, underlies improvement in impaired LV fractional shortening in a pressure overload- and high-salt diet-induced HF mouse model [11]. Therefore, we asked whether TAC surgery and SA4503 treatment altered sympathetic nervous activity. At a 6-week time period, heart rate (HR) was comparable with or without TAC surgery and with or without chronic SA4503 treatment over the last 4-week period (Fig 7A and 7B). Although mean blood pressure (MBP), diastolic blood pressure (DBP) and systolic blood pressure (SBP) significantly decreased in some points among 6 weeks following TAC surgery (MBP; $P<0.01$ and $P<0.05$ vs. sham at 2- and 6-weeks after TAC, DBP; $P<0.01$ vs. sham at 2-weeks after TAC, SBP; $P<0.01$ and $P<0.05$ vs. sham at 2- and 6-weeks after TAC) (Fig 7C, 7E and 7G), chronic treatment with SA4503 over the last 4 weeks did not alter MBP, DBP and SBP (Fig 7D, 7F and 7H). These data suggested that SA4503 at doses used in this study has no effect on sympathetic activity.

Fig 6. Effect of SA4503 and NE-100 on cardiac failure and hypertrophy induced by TAC. A: Representative M-mode echocardiograms of mice treated with or without SA4503 plus or minus NE-100. B: Changes in the percentage of LV fractional shortening (FS%). C: Changes of left ventricular end-systolic diameter (LVEDD). D: Changes of left ventricular end-diastolic diameter (LVEDD). TAC mice were treated with SA4503 (0.1, 0.3 or 1.0 mg/kg) or SA4503 (1.0 mg/kg) plus NE-100 (1.0 mg/kg) as indicated. E: TAC-induced cardiac hypertrophy as indicated by the heart weight/body weight (HW/BW) ratio. Groups consisted of 6–8 mice. Bars represent means ± S.E.M. $F(5, 45) = 12.559$, $P<0.01$ (FS); $F(5, 45) = 10.317$, $P<0.01$ (LVEDD); $F(5, 45) = 3.053$, $P<0.05$ (LVEDD). $F(5, 18) = 8.383$, $P<0.01$ (HW/BW). *, $P<0.05$ and ***, $P<0.01$ versus sham group; #, $P<0.05$ and ##, $P<0.01$ versus the TAC/vehicle-treated group; ††, $P<0.01$ versus the TAC plus SA4503 (1 mg/kg)-treated group.

doi:10.1371/journal.pone.0163992.g006

SA4503 Treatment Affects Sympathetic Nervous Activity as Indicated by Peripheral Blood Pressure

Ito et al. previously reported that suppression of sympathetic nerve activity by a different $\sigma_1$ agonist, PRE084, underlies improvement in impaired LV fractional shortening in a pressure overload- and high-salt diet-induced HF mouse model [11]. Therefore, we asked whether TAC surgery and SA4503 treatment altered sympathetic nervous activity. At a 6-week time period, heart rate (HR) was comparable with or without TAC surgery and with or without chronic SA4503 treatment over the last 4-week period (Fig 7A and 7B). Although mean blood pressure (MBP), diastolic blood pressure (DBP) and systolic blood pressure (SBP) significantly decreased in some points among 6 weeks following TAC surgery (MBP; $P<0.01$ and $P<0.05$ vs. sham at 2- and 6-weeks after TAC, DBP; $P<0.01$ vs. sham at 2-weeks after TAC, SBP; $P<0.01$ and $P<0.05$ vs. sham at 2- and 6-weeks after TAC) (Fig 7C, 7E and 7G), chronic treatment with SA4503 over the last 4 weeks did not alter MBP, DBP and SBP (Fig 7D, 7F and 7H). These data suggested that SA4503 at doses used in this study has no effect on sympathetic activity.
Discussion

Here, we showed that: 1) mice subjected to a TAC-induced hypertrophy model exhibit depression-like behaviors after a prolonged period (6 weeks); 2) these behaviors are closely associated with reduced σ1R expression in hippocampal astrocytes; 3) treatment of mice with the selective σ1R agonist SA4503 ameliorates TAC-induced depression-like behaviors with concomitant improvement of heart function; and 4) increased plasma CORT levels are among causative factors underlying σ1R downregulation and depression-like behaviors following TAC. Taken together, we provide novel evidence for crosstalk between heart failure and depression through the hypothalamic pituitary-adrenal (HPA) axis (Fig 8). Our findings suggest that heart failure-
induced inflammation and stress trigger CORT release via this axis, perturbing σ₁R expression in brain, particularly in the hippocampus. Lower σ₁R activity reduces mitochondrial ATP production, further impairing brain function and resulting in depression. Depression-like behaviors may also aggravate heart function by dysregulating sympathetic nerve activity [11].

Previous reports indicate that neuronal σ₁R downregulation impairs IP₃R-mediated mitochondrial Ca²⁺ transport and ATP production in neurons [9]. ATP serves as not only an energy supply but also acts as an extracellular signaling molecule between neurons and glial cells [27]. For example, in hippocampal slices, norepinephrine treatment promotes glial cell ATP production and increases synaptic transmission efficacy [28]. SA4503 treatment enhances IP₃-mediated Ca²⁺ mobilization into mitochondria and mitochondrial ATP production in cardiomyocytes [8] and heart tissue in vivo (Fig 2F). Our present study reveals that SA4503 treatment antagonizes TAC-induced reduced σ₁R expression in hippocampal astrocytes and enhances ATP production. Cao et al. reported that mice lacking the IP₃ receptor type 2 (Itpr2⁻/⁻) display depression-like behaviors concomitant with reduced ATP levels in prefrontal cortex and hippocampus [29]. They also showed that acute increases in ATP ameliorate depression-like behavior by stimulating the P2X2 receptor. These authors conclude that reduced levels of hippocampal and cortical astrocyte-derived ATP are critical for induction of depression-like behaviors [29]. Combined with our findings, these studies indicate that reduced ATP production followed by σ₁R downregulation in hippocampal astrocytes likely triggers TAC-induced depression-like behavior.

---

**Fig 8. Schematic representation of the hypothesis tested and results obtained.** Shown is a model depicting mechanisms underlying TAC-induced depressive-like behavior, as suggested by findings presented here. TAC-induced cardiac σ₁R downregulation induces cardiac dysfunction. At the same time, levels of peripheral pro-inflammatory cytokines and corticosterone increase, aggravating cardiac dysfunction and downregulating brain hippocampal σ₁R levels. σ₁R stimulation with SA4503 blocks TAC-induced σ₁R downregulation in heart and in hippocampus.

doi:10.1371/journal.pone.0163992.g008
We also found that TAC-dependent σ₁R downregulation in astrocytes occurs primarily in hippocampal CA1 and DG regions. Ito et al. reported that treatment with a different σ₁R agonist, PRE084, antagonizes reduced σ₁R expression seen in brain extracts after aortic banding in mice fed a high-salt diet [11]. We have reported that several σ₁R agonists such as fluvoxamine, pentazocine and SA4503 restore reduced σ₁R levels following heart failure in heart left ventricles [8, 16, 30]. Co-administration of σ₁R antagonist, NE100, blocked those cardioprotective effects, whereas NE-100 administration did not block the elevated σ₁R levels by SA4503 [8, 16, 30]. These results are consistent with the result in hippocampus of TAC mice in this report. Overall, improvement of depressive behaviors by SA4503 in TAC mice is mediated by σ₁R stimulation rather than restoration of σ₁R levels. Thus, mechanism underlying elevation of SA4503-induced σ₁R levels remains unclear.

Unlike previous report [11], TAC with or without SA4503 treatment did not alter sympathetic nerve activity, as evaluated in our study by heart rate and blood pressure analysis. On the other hand, we found that plasma CORT levels increased at 4- and 6-week time points after TAC with concomitant CORT increases in the brain. Furthermore, chronic treatment of TAC mice with CORT significantly reduced hippocampal σ₁R expression, especially in the CA1 region and DG (Fig 4), and mifepristone-mediated glucocorticoid receptor inhibition antagonized this effect in hippocampus (Fig 5). In support of our findings, glucocorticoid receptors are highly expressed in rat hippocampus [31]. In studies of human cohorts exhibiting heart failure, mortality increased significantly in patients with high plasma cortisol, a known risk factor for increased mortality by heart disease [32]. Taken together, increased plasma CORT levels are a risk factor for both reduced hippocampal σ₁R expression and TAC-induced depression-like behaviors. However, further studies are required to define additional factors underlying TAC-induced CORT production and CORT-induced σ₁R downregulation.

Accumulating clinical evidence suggests that depression is a risk factor for cardiac disease and that SSRI treatment reduces post-MI morbidity and mortality following heart failure [3]. Hashimoto et al. recently suggested that σ₁R function links cardiovascular disease to depression [33]. Indeed, mice subjected to aortic banding and infused with the σ₁R agonist PRE084 showed suppressed sympathetic nerve activation with concomitant improvements in cardiac function [11]. However, as noted, our study suggests that SA4503 had no effect on sympathetic nerve activity. Previously, we demonstrated that SA4503 directly stimulates σ₁R in cardiomyocytes, rescuing reduced ATP levels and cardiac dysfunction [8]. Thus, although sympathetic nerve regulation by σ₁R may account for some amelioration of cardiac dysfunction, our study suggests that glucocorticoid receptors likely have a critical function in TAC-induced depression-like behaviors. Interestingly, depressive patients exhibit increased secretions of peripheral stress hormones, including adrenal glucocorticoids, and treatment with anti-depressants including SSRIs normalize that secretion [1]. The plasma levels of cortisol and CORT increase in cardiovascular disease or depressive patients [25, 34], and prescribed treatment with high-dose glucocorticoids is associated with increased risk for cardiovascular disease [35]. A previous report also suggested that inflammatory cytokine levels increase in cardiovascular disease or depressive patients [36, 37]. Moreover, HPA axis is activated following stress with concomitant increases in inflammatory cytokine levels, and increased plasma CORT upregulate pro-inflammatory gene expression [38–41]. Dantzer et al. reported that peripheral lipopolysaccharide (LPS) administration induced both depression-like behavior and pro-inflammatory cytokine production in mice 24 hr later [42]. Relevant to these findings, we showed that brain CORT levels increased in parallel with peripheral CORT levels (1.11±0.11 ng/mg tissue (sham) vs. 1.35±0.16 ng/mg tissue (TAC 6 weeks)), suggestive of an inflammatory response. Overall, we conclude that peripheral induction of pro-inflammatory cytokines by prolonged TAC activates the HPA axis, although further studies are required to define pro-inflammatory cytokines underlying these activities.
Depression-like behaviors induced by chronic CORT administration are often accompanied by concomitant mitochondrial dysfunction, including reduced mitochondrial DNA content and membrane potential [43]. In Flinders rats, a genetic model of depression, depression-like behaviors are associated with decreased numbers of mitochondria in hippocampal neurons [44]. Likewise, overall levels of proteins, DNA, and ATP are significantly reduced in depressive patients [45]. Importantly, σ1R, a MAM-associated protein, and ATP content markedly decreased in hippocampus following prolonged TAC, and depression-like behaviors are closely associated with mitochondrial dysfunction in the hippocampus. Here, we focused on σ1R as it functions as a chaperone for the IP3 receptor, which is critical for ATP production following mitochondrial Ca2+ transport [8, 10, 24]. Heart muscle consumes large amounts of ATP [46], and SA4503 enhances heart ATP production, thereby decreasing cardiac dysfunction. Moreover, other studies suggest that heart disease is a risk factor of neurological disease including depression or cognitive dysfunction [3, 47].

Conclusions
Downregulation of hippocampal σ1R expression was induced by increasing plasma CORT levels following heart dysfunction. The TAC model proved useful to study mechanisms linking cardiovascular disease and depression. We also found that SA4503, a potent and selective σ1R agonist, ameliorates TAC-induced cardiac dysfunction and depression-like behaviors through σ1R upregulation. SA4503 has recently been tested as a treatment for depression in stroke patients in a phase II clinical trial (NCT00639249). Thus, SA4503 is an attractive candidate to prevent depression associated with cardiovascular disease.

Supporting Information
S1 Fig. Effect of paroxetine on depression behaviors. Results of forced swimming test (A) and tail suspension test (B) including paroxetine (Paro) treatment group were shown to compare to SA4503 effect.
(TIFF)

S2 Fig. Effects of TAC and SA4503 treatments on Bip expression. Western blot analyses of Bip and β-tubulin (as a loading control) proteins in the CA1 region and dentate gyrus (DG) of sham and TAC mice.
(TIFF)

Acknowledgments
This work was supported in part by grants-in-aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan (KAKENHI 25293124 and 26102704 to K.F.), the Smoking Research Foundation (K.F.), and from a Research Fellowship from the Japan Society for the Promotion of Science (265570 and 244360 to Y.S. and H.T., respectively).

Author Contributions
Conceptualization: KF MSB.
Data curation: KF.
Formal analysis: MSS.
Funding acquisition: KF.
Investigation: YS HT.
Methodology: HH HK CZ FH.
Project administration: KF.
Resources: CZ FH.
Software: YS.
Supervision: KF.
Validation: HT.
Visualization: YS.
Writing – original draft: YS HT.
Writing – review & editing: KF.

References
1. Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for major depression. Neuropsychopharmacology. 2004; 29(10): 1765–1781. doi: 10.1038/sj.npp.1300506 PMID: 15213704
2. Rumsfeld JS, Havranek E, Masoudi FA, Peterson ED, Jones P, Tooley JF, et al.; Cardiovascular Outcomes Research Consortium. Depressive symptoms are the strongest predictors of short-term declines in health status in patients with heart failure. J Am Coll Cardiol. 2003; 42(10): 1811–1817. PMID: 14642693
3. Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, et al.; ENRICHD Investigators. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction, Arch Gen Psychiatry. 2006; 62(7): 792–798.
4. Rumsfeld JS, Ho PM. Depression and cardiovascular disease: a call for recognition. Circulation. 2005; 111(3): 250–253. doi: 10.1161/01.CIR.0000154573.62822.89 PMID: 15668351
5. Bhuiyan MS, Tagashira H, Fukunaga K. Targeting sigma-1 receptor with fluvoxamine ameliorates pressure-overload-induced hypertrophy and dysfunctions. Expert Opin Ther Targets. 2010; 14(10): 1009–1022. doi: 10.1517/14728222.2010.509348 PMID: 20722474
6. Bhuiyan MS, Tagashira H, Fukunaga K. Crucial interactions between selective serotonin uptake inhibitors and sigma-1 receptor in heart failure. J Pharmacol Sci. 2013; 121(3):177–184. PMID: 23428811
7. Tagashira H, Bhuiyan MS, Shioda N, Hasegawa H, Kanai H, Fukunaga K. Sigma-1 receptor stimulation with fluvoxamine ameliorates transverse aortic constriction-induced myocardial hypertrophy and dysfunction in mice. Am J Physiol Heart Circ Physiol. 2010; 299(5): H1535–H1545. doi: 10.1152/ajpheart.00198.2010 PMID: 20802134
8. Tagashira H, Zhang C, Lu YM, Hasegawa H, Kanai H, Han F, et al. Stimulation of α1-receptor restores abnormal mitochondrial Ca(2+) mobilization and ATP production following cardiac hypertrophy. Biochim Biophys Acta. 2013; 1830(4): 3082–3094. doi: 10.1016/j.bbagen.2012.12.029 PMID: 23298811
9. Shioda N, Ishikawa K, Tagashira H, Ishizuaka T, Yawo H, Fukunaga K. Expression of a truncated form of the endoplasmic reticulum chaperone protein, sigma-1 receptor, promotes mitochondrial energy depletion and apoptosis. J Biol Chem. 2012; 287(28): 23318–23331. doi: 10.1074/jbc.M112.349142 PMID: 22619170
10. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell. 2007; 131: 596–610. doi: 10.1016/j.cell.2007.08.036 PMID: 17981125
11. Ito K, Hirooka Y, Matsukawa R, Nakano M, Sunagawa K. Decreased brain sigma-1 receptor contributes to the relationship between heart failure and depression. Cardiovasc Res. 2012; 93(1): 33–40. doi: 10.1093/cvr/cvs255 PMID: 21960687
12. Fujimura K, Matsumoto J, Niwa M, Kobayashi T, Kawashima Y, In Y, et al. Synthesis, structure, and quantitative structure-activity relationships of sigma receptor ligands, 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl) piperazines. Bioorg Med Chem. 1997; 5(8): 1675–1683. PMID: 9313869
13. Ago Y, Anikawa S, Yata M, Yano K, Abe M, Takuma K, et al. Antidepressant-like effects of the glucocorticoid receptor antagonist RU-43044 are associated with changes in prefrontal dopamine in mouse
models of depression. Neuropharmacology. 2008; 55(8): 1355–1363. doi: 10.1016/j.neuropharm.2008.08.026 PMID: 18796307

14. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology. 1985; 85(3): 367–370. PMID: 3923523

15. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther. 1977; 229(2): 327–336. PMID: 569892

16. Tagashira H, Bhuiyan MS, Shioda N, Fukunaka K. Distinct cardioprotective effects of 17$\beta$-estradiol and dehydroepiandrosterone on pressure-overload-induced hypertrophy in ovariectomized female rats. Menopause. 2011; 18 (12): 1317–1326. doi: 10.1097/gme.0b013e3182f1915b PMID: 21844826

17. Tagashira H, Bhuiyan MS, Fukunaka K. Diverse regulation of IP$_3$ and ryanodine receptors by pentazocine through $\sigma_1$-receptor in cardiomyocytes. Am J Physiol Heart Circ Physiol. 2013; 305(8): H1201–H1212. doi: 10.1152/ajpheart.00330.2013 PMID: 23934856

18. Tagashira H, Bhuiyan MS, Shioda N, Fukunaga K. Fluvoxamine rescues mitochondrial Ca$^{2+}$ transport and ATP production through $\sigma_1$-receptor in hypertrophic cardiomyocytes. Life Sci. 2014; 95(2): 89–100. doi: 10.1016/j.lfs.2013.12.019 PMID: 23934856

19. Silverman MN, Mukhopadhyay P, Belyavskaya E, Tonelli LH, Revenis BD, Doran JH, et al. Glucocorticoid receptor dimerization is required for proper recovery of LPS-induced inflammation, sickness behavior and metabolism in mice. Mol Psychiatry. 2013; 18(9): 1006–1017. doi: 10.1038/mp.2012.131 PMID: 23089634

20. Shioda N, Beppu H, Fukuda T, Li E, Kitajima I, Fukunaga K. Aberrant calcium/calcmodulin-dependent protein kinase II (CaMK II) activity is associated with abnormal dendritic spine morphology in the ATRX mutant mouse brain. J Neurosci. 2011; 31(1): 346–358. doi: 10.1523/JNEUROSCI.4816-10.2011 PMID: 21209221

21. Shioda N, Yamamoto Y, Watanabe M, Binas B, Owada Y, Fukunaka K. Heart-type fatty acid binding protein regulates dopamine D2 receptor function in mouse brain. J Neurosci. 2010; 30(8): 3146–3155. doi: 10.1523/JNEUROSCI.4140-09.2010 PMID: 20181611

22. Wang D, Noda Y, Tsunekawa H, Zhou Y, Miyazaki M, Senzaki K, et al. Role of N-methyl-D-aspartate receptors in antidepressant-like activity of sigma-1 receptor agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenoxypropyl)piperazine dihydrochloride (SA-4503) in olfactory bulbectomized rats. J Pharmacol Exp Ther. 2007; 322(3):1305–1314. doi: 10.1124/jpet.124685 PMID: 17556637

23. Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol. 1996; 307(1): 117–119. PMID: 8831113

24. Gregus A, Wintink AJ, Davis AC, Kalynchuk LE. Effect of repeated corticosterone injections and restraint stress on anxiety and depression-like behavior in male rats. Behav Brain Res. 2005; 156(1): 105–114. doi: 10.1016/j.bbr.2004.05.013 PMID: 15474655

25. Nemerooff CB, Widerlöv E, Bissette G, Wallén H, Karlsson I, Eklund K, et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science. 1984; 226 (4680): 1342–1344. PMID: 6334652

26. Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res. 2002; 53(4): 865–871. PMID: 12377295

27. Fields RD, Burnstock G. Purinergic signalling in neuron-glia interactions. Nat Rev Neurosci. 2006; 7 (6): 423–436. doi: 10.1038/nn1928 PMID: 16715052

28. Gordon GR, Baimoukhametova DV, Hewitt SA, Rajapaksha WR, Fisher TE, Bains JS. Norepinephrine triggers release of glial ATP to increase postsynaptic efficacy. Nat Neurosci. 2005; 8(8): 1078–1086. doi: 10.1038/nn1498 PMID: 15995701

29. Cao X, Li LP, Wang Q, Wu Q, Hu HH, Zhang M, et al. Astrocyte-derived ATP modulates depressive-like behaviors. Nat Med. 2013; 19(6): 773–777. doi: 10.1038/nm.3162 PMID: 23644515

30. Tagashira H, Matsumoto T, Taguchi K, Zhang C, Han F, Nemoto S et al. Vascular endothelial $\sigma_1$-receptor stimulation with SA4503 rescues aortic relaxation via Akt/eNOS signaling in ovariectomized rats with aortic banding. Circ J. 2013; 77(11): 2831–2840. PMID: 23965801

31. Reul JM, de Kloet ER. Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology. 1985; 117(6): 2505–2511. doi: 10.1210/endo-117-6-2505 PMID: 2998738

32. Yamaji M, Tsutamoto T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, et al. Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress. Circ Heart Fail. 2009; 2(6): 608–615. doi: 10.1161/CIRCHEARTFAILURE.109.868513 PMID: 19919986
33. Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol. 2013; 100: 15–29. doi: 10.1016/j.pneurobio.2012.09.001 PMID: 23044468

34. Güder G, Bauersachs J, Frantz S, Weismann D, Alolio B, Ertl G, et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation. 2007; 115(13): 1754–1761. doi: 10.1161/CIRCULATIONAHA.106.653964 PMID: 17572171

35. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004; 141(10): 764–770. PMID: 15545676

36. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010; 67(5): 446–457. doi: 10.1016/j.biopsych.2009.09.033 PMID: 20015486

37. Katz SD, Rao R, Berman JW, Schwarz M, Demopoulos L, Bijou R, et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation. 1994; 90(1): 12–16. PMID: 8025986

38. Chaouloff F. Physiopharmacological interactions between stress hormones and central serotonergic systems. Brain Res Brain Res Rev. 1993; 18(1): 1–32. PMID: 8467346

39. Eisenberger NI, Cole SW. Social neuroscience and health: neurophysiological mechanisms linking social ties with physical health. Nat Neurosci. 2012; 15(5): 669–679. doi: 10.1038/nn.3086 PMID: 22504347

40. Haddad JJ, Saade NE, Safieh-Garabedian B. Cytokines and neuro-immune-endocrine interactions: a role for the hypothalamic-pituitary-adrenal revolving axis. J Neuroimmunol. 2002; 133(1–2): 1–13. PMID: 12446003

41. Zunszain PA, Anacker C, Cattaneo A, Carvalho LA, Pariante CM. Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35(3): 722–729. doi: 10.1016/j.pnpbp.2010.04.011 PMID: 20406665

42. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008; 9(1): 46–56. doi: 10.1038/nrn2297 PMID: 18073775

43. Liu W, Zhou C. Corticosterone reduces brain mitochondrial function and expression of mitofusin, BDNF in depression-like rodents regardless of exercise preconditioning. Psychoneuroendocrinology. 2012; 37(7): 1057–1070. doi: 10.1016/j.psyneuen.2011.12.003 PMID: 22244747

44. Chen F, Wegener G, Madsen TM, Nyengaard JR. Mitochondrial plasticity of the hippocampus in a genetic rat model of depression after antidepressant treatment. Synapse. 2013; 67(3): 127–134. doi: 10.1002/syn.21622 PMID: 23152197

45. Beasley CL, Pennington K, Behan A, Wait R, Dunn MJ, Cotter D. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: Evidence for disease-associated changes. Proteomics. 2006; 6(11): 3414–3425. doi: 10.1002/pmic.200500069 PMID: 16637010

46. Lopaschuk GD, Ussher JR, Holmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010; 90(1): 207–258. doi: 10.1152/physrev.00015.2009 PMID: 20086077

47. Zuccalà G, Cattel C, Manes-Gravina E, Di Niro MG, Cocchi A, Bernabei R. Left ventricular dysfunction: a clue to cognitive impairment in older patients with heart failure. J Neurol Neurosurg Psychiatry. 1997; 63(4): 509–512. PMID: 9343133